YERVOY (E.R. Squibb & Sons, L.L.C.)


Welcome to the PulseAid listing for the YERVOY drug offered from E.R. Squibb & Sons, L.L.C.. This CTLA-4-directed Blocking Antibody [EPC],CTLA-4-directed Antibody Interactions [MoA],Increased T Lymphocyte Activation [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: E.R. Squibb & Sons, L.L.C.
NON-PROPRIETARY NAME: ipilimumab
SUBSTANCE NAME: IPILIMUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: CTLA-4-directed Blocking Antibody [EPC],CTLA-4-directed Antibody Interactions [MoA],Increased T Lymphocyte Activation [PE]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2011-03-25
END MARKETING DATE: 0000-00-00


YERVOY HUMAN PRESCRIPTION DRUG Details:

Item DescriptionYERVOY from E.R. Squibb & Sons, L.L.C.
LABELER NAME: E.R. Squibb & Sons, L.L.C.
DEA SCHEDULE:
ACTIVE STRENGTH: 5(mg/mL)
START MARKETING DATE: 2011-03-25
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0003-2327_f5b93ca8-1cae-4c0e-9363-cd09a1d83ac1
PRODUCT NDC: 0003-2327
APPLICATION NUMBER: BLA125377

Other IPILIMUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
E.R. Squibb & Sons, L.L.C.YERVOY